DLA Piper’s patent advice to Neurim not privileged, court hears
David Shavin 2018-05-17 9:50 pm By Miklos Bolza | Sydney
Please login to bookmark Close

Two generic drug makers are fighting for access to confidential documents related to amendments by Neurim Pharmaceutical of patents covering its sleep drug Circadin, telling the Federal Court on Thursday privilege had been waived after a phone conversation between the company’s founder and her lawyers from DLA Piper.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au